No article text was recorded for this version.
therapeutic window optimization
Version 1 of 120 papers23 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis
- Blog: Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
- Blog: Reinforcement Learning with Action-Derived Rewards for Chemotherapy and Clinical Trial Dosing Regimen Selection
- Blog: The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun
- Blog: Safe and Interpretable Estimation of Optimal Treatment Regimes
- Blog: A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- Blog: Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23
- Blog: Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- Blog: Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
- Blog: ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity
- Blog: Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study
- Blog: QuTIE: quantum optimization for target identification by enzymes
- Blog: Emodin induces Panc-1 cell apoptosis via declining the mitochondrial membrane potential
- Blog: Safe Exploration in Dose Finding Clinical Trials with Heterogeneous Participants
- Blog: 1196 Streamlining T cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine
- Blog: Synthetic Analogue of Butenolide as an Antifouling Agent
- Blog: Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
- Blog: Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
- Blog: The effect of GSK-3β in arsenic-induced apoptosis of malignant tumor cells: a systematic review and meta-analysis
- Blog: FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
History & citation
Current · Permanent link
- This direction split from Decoupling Therapeutic Potency from Systemic Toxicity (70% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_therapeutic_window_optimization_15aafded,
title = {therapeutic window optimization},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-window-optimization/rdr_15aafdeda7024cc0b1b83599e7eac001},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 1, frozen text):
@misc{lacuna_therapeutic_window_optimization_15aafded_v1,
title = {therapeutic window optimization},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-window-optimization/rdr_15aafdeda7024cc0b1b83599e7eac001/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}